University of Gothenburg research suggests blocking somatostatin may prevent hypoglycemia in type 1 diabetes patients.
Research from the University of Gothenburg, published in "Nature Metabolism," suggests that blocking the hormone somatostatin may prevent dangerous blood sugar drops in type 1 diabetes. In patients, excess somatostatin inhibits glucagon release, leading to hypoglycemia. Experiments with mice showed that inhibiting somatostatin restored glucagon release, highlighting a new potential treatment strategy that could reduce life-threatening low blood sugar risks.
6 months ago
8 Articles
Articles
Further Reading
You have 14 free stories remaining this month. Subscribe anytime for unlimited access.